Latest / The BioHub - by Avetix
Episode 119 - Erik van den Berg - CEO of Memo Therapeutics
Prior to JPM 2026 and the news of their recent CSL collaboration, I spoke to Memo Therapeutics' CEO, Erik van den Berg for an episode of The BioHub Podcast.
Memo are preparing for a global ph3 trial of Potravitug, their antibody against BK polyomavirus infection in kidney transplant recipients. BKPyV infection can lead to nephropathy, loss of kidney function, as well as organ failure, rejection & death, with the virus residing in up to 90% of the total population.
Erik joins us to walk through Memo's late-stage plans, as well as their DROPZYLLA platform, and their early stage oncology…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.